# A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

> **NCT03024177** · PHASE2 · WITHDRAWN · sponsor: **Vaxart**

## Conditions studied

- Rhinovirus
- Upper Respiratory Tract Infection

## Interventions

- **DRUG:** Vapendavir
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03024177
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-04
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is withdrawn due to company decision
- **Last updated:** 2018-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024177, "A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03024177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*